Skip to main content
F
Formulate
Jobs
Companies
Drugs
Advisor
NEW
Insider Intel
Salary
Pricing
Toggle theme
Toggle theme
Menu
argenx Jobs | Formulate
Jobs
argenx
argenx Jobs
Belgium - Zwijnaarde
Biotechnology
argenx is a life sciences company focused on Antibody therapies.
12
open positions at argenx
View Full Profile
Filters:
Oncology ×
Manager, MRC Operations
argenx
Posted 1w ago
Boston, MA, USA
Full-time
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Field Reimbursement Manager, Mid-Atlantic East
argenx
Posted 2w ago
Raritan
Full-time
Field Reimbursement Manager, Spring Field MO
argenx
Posted 2w ago
Springfield, MO
$176K - $242K
Full-time
Field Reimbursement Manager, Philly
argenx
Posted 2w ago
Philadelphia
$176K - $242K
Full-time
Field Reimbursement Manager, New England
argenx
Posted 2w ago
Springfield, MA; Albany
$176K - $242K
Full-time
Field Reimbursement Manager, Wisconsin
argenx
Posted 2w ago
Milwaukee
$176K - $242K
Full-time
Field Reimbursement Manager, Austin TX
argenx
Posted 2w ago
San Antonio
$176K - $242K
Full-time
Field Reimbursement Manager, Bluegrass West
argenx
Posted 2w ago
Lexington; Louisville; Cincinnati
$176K - $242K
Full-time
Field Reimbursement Manager, Ann Arbor
argenx
Posted 2w ago
Ann Arbor; Toledo
$176K - $242K
Full-time
Field Reimbursement Manager, Mississippi
argenx
Posted 2w ago
Jackson
$176K - $242K
Full-time
Field Reimbursement Manager, West Atlanta
argenx
Posted 2w ago
Atlanta; Marieta
$176K - $242K
Full-time
Field Reimbursement Manager - Orlando, FL
argenx
Posted 1mo ago
Orlando
Full-time
Company Overview
Active Jobs
171
Pipeline Programs
88
Drug Products
2
Clinical Trials
91
View Full Company Profile
Therapeutic Areas
Neurology
Immunology
Oncology
Links
Company Website
Careers Page
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Oncology
MANAGER
H-1B · 1 FY23
Hematology
Rare Diseases